About the Authors

Miriam Calao

Roles Conceptualization, Methodology, Writing – original draft, Writing – review & editing

miriam.calao@abbvie.com

Affiliation Abbvie Pty Ltd, Mascot, New South Wales, Australia

Jodie L. Wilson

Roles Conceptualization, Methodology, Writing – original draft, Writing – review & editing

Affiliation Abbvie Pty Ltd, Mascot, New South Wales, Australia

Lynda Spelman

Roles Conceptualization, Investigation, Methodology, Writing – original draft, Writing – review & editing

Affiliation Veracity Clinical Research, Woolloongabba, Queensland, Australia

Laurent Billot

Roles Conceptualization, Data curation, Formal analysis, Methodology, Writing – original draft, Writing – review & editing

Affiliation The George Institute for Global Health, Sydney, New South Wales, Australia

Diana Rubel

Roles Conceptualization, Investigation, Methodology, Writing – original draft, Writing – review & editing

Affiliation Woden Dermatology, Canberra, Australian Capital Territory, Australia

Alan D. Watts

Contributed equally to this work with: Alan D. Watts, Gregor B. E. Jemec

Roles Conceptualization, Funding acquisition, Methodology, Writing – original draft, Writing – review & editing

Affiliation Abbvie Pty Ltd, Mascot, New South Wales, Australia

Gregor B. E. Jemec

Contributed equally to this work with: Alan D. Watts, Gregor B. E. Jemec

Roles Conceptualization, Investigation, Methodology, Writing – original draft, Writing – review & editing

Affiliation Department of Dermatology, Roskilde Hospital, Health Sciences Faculty, University of Copenhagen, Roskilde, Denmark

Competing Interests

AbbVie Pty Ltd funded the research for these studies and participated in the studies design; studies research; analysis and interpretation of data; and writing, reviewing and approving of this publication. This does not alter the authors’ adherence to PLOS ONE policies on sharing data and materials. M Calao, JL Wilson, A Watts receive a salary as employees of AbbVie and may also receive AbbVie stock and/or stock grants. D Rubel is principal investigator for the following HS studies: M11-810 and M12-555, HS registry H13-147, HS validation study 10610, and HS epidemiology study 10756, as well as M13-674 Adalimumab nail psoriasis study; and has served on the Advisory Boards for Abbvie, Eli Lilly, Celgene, Galderma, GlaxoSmithKline, Janssen, Leo Pharma, Novartis, and Sanofi. L Spelman has served on the advisory Boards for Abbvie, Eli Lilly, Novartis and Sanofi; and undertakes sponsored clinical research for AbbVie, Amgen, Ascend Biopharmaceuticals, Australian Wool Innovation Limited, Celgene, Dermira, Eli Lilly, Galderma, Genentech, GlaxoSmithKline, Leo Pharma, Merck, Novartis, Phosphagenics, Regeneron, and has received sponsored travel from AbbVie, Novartis, and Janssen- Cilag. GB Jemec disclosures are as follows: AbbVie: Adboard, consultant, investigator, speaker, unrestricted grant. Coloplast: Consultant, speaker. Leo pharma: Consultant, investigator, speaker, unrestricted grant. Galderma: Speaker. Janssen-Pharma: Adboard MSD: Adboard. Novartis: Adboard, consultant, investigator, unrestricted grant. Regeneron: Investigator. UCB: Consultant and investigator. InflaRX: Consultant and investigator. L Billot is an employee of The George Institute for Global Health which has received payment from AbbVie for the conduct and analysis of the prevalence study.